Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CPB1 | P15086 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.59 |
| ▸ | KLK7 | P49862 | 2/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.55 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22834040 | 1.00 | MAPT (0.59) | MAPTCPB1CPB2KLK7KLK5 | |
| SCHEMBL7316805 | 0.93 | MAPT (0.64) | MAPTCPB1CPB2KLK7KLK5 | |
| SCHEMBL21219294 | 0.93 | REN (0.57) | MAPTCPB1CPB2KLK7KLK5 | |
| SCHEMBL21219296 | 0.93 | REN (0.57) | MAPTCPB1CPB2KLK7KLK5 | |
| SCHEMBL21981385 | 0.93 | CAPN1 (0.59) | CPB1CPB2FOLH1CAPN1CAPN2 | |
| SCHEMBL24130643 | 0.92 | KLK7 (0.59) | MAPTKLK7KLK5CAPN1CAPN2 | |
| SCHEMBL24130639 | 0.92 | KLK7 (0.59) | MAPTKLK7KLK5CAPN1CAPN2 | |
| SCHEMBL17039826 | 0.89 | FOLH1 (0.60) | MAPTCPB1CPB2KLK7KLK5 | |
| SCHEMBL21981425 | 0.89 | CAPN1 (0.58) | CPB1CPB2CAPN1CAPN2 | |
| SCHEMBL21981423 | 0.89 | CAPN1 (0.58) | CPB1CPB2CAPN1CAPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | WASHINGTON UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | WASHINGTON UNIVERSITY (US) | 2022-12-01 | — | — | US | disclosed |
| EP-3989997-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | Washington University (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264187-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | JANETKA JAMES (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590123-B2 | Compounds and methods for treating cancer, viral infections, and allergic conditions | TMPRSS2, TMPRSS4, F2RL3 | MAPT 3390/4885CPB1 134/4885CPB2 112/4885 |
| US-20220380407-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | TMPRSS2, PRSS1, PRSS2 | MAPT 1977/4885CPB1 87/4885CPB2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.